D-青霉胺：从药理学和监管角度看人类和犬类的最新情况。
D-Penicillamine: The State of the Art in Humans and in Dogs from a Pharmacological and Regulatory Perspective.
作者信息
Pugliese Michela, Biondi Vito, Gugliandolo Enrico, Licata Patrizia, Peritore Alessio Filippo, Crupi Rosalia, Passantino Annamaria
机构信息
Department of Veterinary Science, University of Messina, 98166 Messina, Italy.
Department of Chemical, Biological, Pharmaceutical, and Environmental Science, University of Messina, 98168 Messina, Italy.
出版信息
Antibiotics (Basel). 2021 May 28;10(6):648. doi: 10.3390/antibiotics10060648.
Chelant agents are the mainstay of treatment in copper-associated hepatitis in humans, where D-penicillamine is the chelant agent of first choice. In veterinary medicine, the use of D-penicillamine has increased with the recent recognition of copper-associated hepatopathies that occur in several breeds of dogs. Although the different regulatory authorities in the world (United States Food and Drugs Administration-U.S. FDA, European Medicines Agency-EMEA, etc.) do not approve D-penicillamine for use in dogs, it has been used to treat copper-associated hepatitis in dogs since the 1970s, and is prescribed legally by veterinarians as an extra-label drug to treat this disease and alleviate suffering. The present study aims to: (a) address the pharmacological features; (b) outline the clinical scenario underlying the increased interest in D-penicillamine by overviewing the evolution of its main therapeutic goals in humans and dogs; and finally, (c) provide a discussion on its use and prescription in veterinary medicine from a regulatory perspective.
螯合剂是人类铜相关肝炎治疗的主要手段，其中D-青霉胺是首选螯合剂。在兽医学中，随着最近对几种犬种中发生的铜相关肝病的认识增加，D-青霉胺的使用也有所增加。尽管世界上不同的监管机构（美国食品药品监督管理局 - 美国FDA、欧洲药品管理局 - EMEA等）未批准D-青霉胺用于犬类，但自20世纪70年代以来它一直被用于治疗犬类铜相关肝炎，并且兽医将其作为超说明书用药合法开具以治疗这种疾病并减轻痛苦。本研究旨在：（a）阐述其药理学特征；（b）通过概述其在人和犬中的主要治疗目标的演变，概述对D-青霉胺兴趣增加背后的临床情况；最后，（c）从监管角度对其在兽医学中的使用和处方进行讨论。
Zotero 插件